The owners of this one trick pony thought they had a star performer so prized themselves sky high.Now that they have understood what sales resistance means they need to reformulate their strategy. Since they dont have a R&D portfolio in trial stage , they should sell the CO. to a deep pocketed major pharma . The max they may get is %16 at best.
Agree..Already high debt (yes, lots of cash), with high SG&A costs to enter into new markets with an already overburdened R&D expense. Are they searching for new indications for this drug, and what additional R&D expenses will be needed for these new indication? Take the money and run...
Kinda funny approach, build a drug then go hunting for diseases for which it might apply, as opposed to finding out what causes the disease and then building a drug to treat that. Seems like this approach could only happen for TGF-b or IFNg or the big players in the immune system.
This is one trick pony, but the odds for drug approval look good. They have a lot of cash and drug approval in numerous other countries with about 30% of the shares short. Any good news and this stock will FLY. If they get FDA approval, a major drug firm will make a bid for this company. Just bought last week and going to buy more.
Hmm..they said that about HGSI and it was bought out a few months ago...You should also be loading up on Dendreon. It's been crushed in spite of continuous good news. Actually, it's been manipulated, but someones loss can be your gain if you have an IQ over 90.